S&P Futures
4,434.50 -7.75 (-0.17%) Dow Futures
34,533.00 -61.00 (-0.18%) Nasdaq Futures
15,054.75 -37.75 (-0.25%) Russell 2000 Futures
1,868.50 -4.80 (-0.26%) Crude Oil
80.59 +0.49 (+0.61%) Gold
1,942.30 -4.50 (-0.23%)
Apexigen, Inc. (APGN)
| Previous Close | 0.3851 |
| Open | 0.3601 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 2200 |
| Day's Range | 0.3851 - 0.3851 |
| 52 Week Range | 0.3310 - 8.2800 |
| Volume | |
| Avg. Volume | 59,149 |
| Market Cap | 9.574M |
| Beta (5Y Monthly) | 3.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.64 |
GlobeNewswireApexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial - SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focu
ZacksApexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
BenzingaSmall SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M
Pyxis Oncology Inc (NASDAQ: PYXS) agreed to acquire Apexigen Inc (NASDAQ: APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share. Apexigen went public in a blank-check deal just last summer. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million. In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%. "This acquisition uniquely positions Pyxis O
